Abstract
The process and progress of submissions to PHARMAC for funding of new treatments is unclear. There appears to be a lack of communication or transparency regarding funding applications, decisions, or expected timelines to reach an endpoint. It is difficult to have confidence in a process that lacks such definition. A recent clinician submission for funding of an oncology treatment (gemcitabine) for bladder cancer highlights these issues.
MeSH terms
-
Antimetabolites, Antineoplastic / economics
-
Antimetabolites, Antineoplastic / therapeutic use*
-
Carcinoma, Transitional Cell / drug therapy*
-
Deoxycytidine / analogs & derivatives*
-
Deoxycytidine / economics
-
Deoxycytidine / therapeutic use
-
Drug Approval / economics*
-
Gemcitabine
-
Humans
-
National Health Programs / economics
-
New Zealand
-
Urinary Bladder Neoplasms / drug therapy*
Substances
-
Antimetabolites, Antineoplastic
-
Deoxycytidine
-
Gemcitabine